Physician profile
Alison A Bailey
NPI 1043214844
$4,513.45
in general payments reported to CMS, 2019-2025
11 companies · $861 in 2025
The $861 reported for 2025 was more than what 89% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $217 · 2020: $68.16 · 2021: $160 · 2022: $208 · 2023: $2,209 · 2024: $791 · 2025: $861.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,337 · Consulting Fee: $1,512 · Education: $11.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,336.59 |
| Consulting Fee | $1,512.00 |
| Education | $11.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,630.74 | 2023 | |
| Bausch & Lomb Americas INC. | $1,137.83 | 2023-2025 | Infuse, Btod, Xiidra |
| Coopervision INC. | $959.49 | 2019-2025 | Myday Contact Lens, Cvi Contact Lens, Misight Contact Lens |
| Johnson & Johnson Vision Care, INC. | $180.66 | 2021-2025 | Acuvue |
| Alcon Vision LLC | $170.85 | 2019-2025 | Precision 1, Dailies Total1, Total30 |
| Sun Pharmaceutical Industries INC. | $144.01 | 2022-2023 | Cequa |
| Abbvie INC. | $117.12 | 2023 | |
| Rxsight INC | $88.24 | 2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $45.92 | 2020 | |
| Sight Sciences, INC. | $21.69 | 2024 | Tearcare System |
| Allergan, INC. | $16.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alison Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.